Skye Bioscience disclosed interim 52‑week results from the extension phase of its Phase 2a CBeyond study evaluating nimacimab (a peripherally‑restricted CB1 inhibitor antibody) in combination with semaglutide. The company reported positive signals from the combination arms, describing safety and efficacy trends that support continued development in obesity and metabolic disorders. Skye framed the results as proof‑of‑concept for peripheral CB1 blockade combined with GLP‑1 receptor agonism and said next operational steps will focus on late‑stage planning and partnership conversations.